Form 4: CEO Shao-Lee Lin Increases Stake in Cue Biopharma

Cue Biopharma CEO Shao-Lee Lin acquired pre-funded warrants and common stock warrants through a private placement.

Summary

• CEO Shao-Lee Lin acquired 90,906 pre-funded warrants and 45,453 common stock warrants.
• The transaction occurred on June 1, 2026, following stockholder approval at a Special Meeting.
• The securities were purchased as part of a private placement agreement originally entered into on April 30, 2026.
• The purchase price for the units (one pre-funded warrant and one-half common stock warrant) was $11.00.
• The securities are held indirectly through the Shao-Lee Lin Trust.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal of management confidence, as the CEO is personally investing capital into the company via a private placement.

Positives

• Insider confidence demonstrated by the CEO's participation in the private placement.
• Successful completion of the private placement following necessary stockholder approval.

Negatives

• Dilutive impact of issuing additional warrants and potential future common stock.

Risks

• Market volatility associated with biotech equity securities.
• Dependence on future exercise of warrants for capital realization.
• Regulatory and listing rule compliance requirements.

Future Outlook

The warrants are exercisable as of June 1, 2026, with the common stock warrants expiring on May 4, 2031.

Industry Context

StockSavvy.ai notes that insider participation in private placements is a common mechanism in the biotechnology sector to signal management alignment with shareholders during capital-raising initiatives.

Comparison to Industry Standards

• The use of pre-funded warrants is a standard practice for biotech companies to raise capital while deferring immediate dilution until shareholder approval is obtained.
• Insider participation in private placements is generally viewed as a positive governance signal in the small-cap biotech industry.

Corporate Governance

Related Party Transactions

• The reporting person, CEO Shao-Lee Lin, participated in the private placement as an accredited investor.

Stakeholder Impact

• Shareholders may experience dilution upon the exercise of the warrants.
• The capital raise provides the company with additional liquidity to fund operations.

Next Steps

• Potential exercise of pre-funded warrants by the reporting person.
• Potential exercise of common stock warrants prior to the May 4, 2031 expiration date.

Key Dates

Keywords

Cue Biopharma, CUE, Insider Trading, Form 4, Biotech, Private Placement, Warrants